AzTrials
AzTrials

AnesthesiaNCT06883279

Effect of Interscalene Block Methods on Rebound Pain

A study testing Intraplexus and Extraplexus in people with Anesthesia and Pain, Shoulder, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In this study, the hypothesis that local anesthesia, not directly injected into the nerve root, may reduce the incidence of rebound pain in the interscalene block with an extraplexus approach during arthroscopic shoulder surgeries will be investigated. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Anesthesia, Pain, Shoulder, Pain, Postoperative
What is being tested?
Intraplexus and Extraplexus
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
85 participants
Where
1 siteTurkey (Türkiye)
Study dates
20 Mar 2025to 20 Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients aged 18-65 years.
  • Patients with ASA physical status I or II.
  • Patients planned for arthroscopic shoulder surgery in the lateral decubitus position with interscalene nerve block.

Who cannot join

  • Patients who do not consent to participate in the study.
  • Block failure.
  • Language acquisition deficiency.
  • Obesity (body mass index > 35 kg/m²).
  • Diabetes.
  • Psychiatric disorders.
Show all 21Show fewer
  • Central nervous system diseases.
  • Vestibular diseases.
  • Presence of neuropathy and paralysis.
  • Pregnancy.
  • Previous open shoulder surgery.
  • Allergy to local anesthetics.
  • Coagulopathy.
  • Severe thrombocytopenia.
  • Infection at the puncture site.
  • Pre-existing neuropathy in the limb to be operated.
  • Use of dexamethasone.
  • Use of opioid and antiemetic medications before surgery.
  • Severe cardiopulmonary disease.
  • Low baseline oxygen saturation.
  • Conditions that prevent cooperation in the postoperative period (e.g., mental retardation, delirium).

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ankara Bilkent City Hospital

    Ankara, Ankara, Çankaya, 06800

Other trials in Turkey (Türkiye)

About this study

Official title: Effect of Intraplexus and Extraplexus Interscalene Block Approaches on the Incidence of Rebound Pain in Arthroscopic Shoulder Surgery: A Prospective, Randomized, Double-Blind Clinical Study

In this study, the hypothesis that local anesthesia, not directly injected into the nerve root, may reduce the incidence of rebound pain in the interscalene block with an extraplexus approach during arthroscopic shoulder surgeries will be investigated. Rebound pain is defined as a short-term but severe pain before and after the resolution of the interscalene block and will be evaluated using the Numerical Rating Scale (NRS) (NRS ≥ 7).

Read the detailed description

The study will include patients aged 18-65 years, with an American Society of Anesthesiologists (ASA) physical status of I or II, scheduled for arthroscopic shoulder surgery in the lateral decubitus position, accompanied by interscalene nerve block performed by the same surgeon. Patient characteristics (age, gender, body mass index, etc.), block procedure duration, number of needle passes, onset time of sensory block, onset time of motor block, and possible complications related to the block (paresthesia, Horner's syndrome, dyspnea, hoarseness), postoperative nausea and vomiting (PONV) status, and Quality of Recovery-15 (QoR-15) scores on the preoperative first day and postoperative days 1 and 7 will be recorded. The primary outcome parameter will be the incidence of rebound pain. Rebound pain will be defined as a short-term but severe pain before and after the resolution of the interscalene block, assessed using the Numerical Rating Scale (NRS) (NRS ≥ 7). Secondary outcomes will include the number of needle passes, block application time, onset time of sensory block, onset time of motor block, intraoperative dexmedetomidine requirement, duration of block effectiveness, postoperative pain, PONV, need for rescue analgesics, incidence of paresthesia and Horner's syndrome, dyspnea, hoarseness, duration of stay in the recovery room, duration of rebound pain, and postoperative Quality of Recovery-15 (QoR-15) scores.

Being tested
Intraplexus, Extraplexus
Keywords
Anesthesia, Interscalene block, Rebound pain
Medical subject headings
Shoulder Pain, Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IntraplexusOther

    The block needle will be advanced from the middle scalene muscle in a posterior-anterior direction and advanced between the C5-C6 nerve roots and the injection will be performed

  • ExtraplexusOther

    The block needle will first be advanced above the C5 nerve root and towards the anterior part of the brachial plexus and 10 ml of local anesthetic will be injected. Then, the needle will be withdrawn to the posterior surface of the brachial plexus and 10 ml of local anesthetic will be administered.

Study groups in NCT06883279
Study groupRoleWhat they receive
Intraplexus approach in interscalene blockActive comparatorThe block needle will be advanced from the middle scalene muscle in a posterior-anterior direction and advanced between the C5-C6 nerve roots and the injection will be performed
Receives: Other: Intraplexus
Extraplexus approach in interscalene blockActive comparatorThe block needle will first be advanced above the C5 nerve root and towards the anterior part of the brachial plexus and 10 ml of local anesthetic will be injected. Then, the needle will be withdrawn to the posterior surface of the brachial plexus and 10 ml of local anesthetic will be administered.
Receives: Other: Extraplexus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rebound pain

    Pain will be evaluated using the 0-10 Numerical Rating Scale (NRS), where 0 represents no pain and 10 represents the worst possible pain. Rebound pain will be defined as a short-term but severe pain occurring before and after the resolution of the interscalene block (NRS ≥ 7).

    Measured: 36 hours

Secondary outcomes (16)
  1. Number of needle passes

    Number of times the needle is withdrawn and reinserted

    Measured: During the block procedure time

  2. Block performance time

    Time from the placement of the block needle to the completion of local anesthetic injection (minutes)

    Measured: During the block procedure time

  3. Rescue analgesic

    Pain will be evaluated using the 0-10 Numerical Rating Scale (NRS), where 0 represents no pain and 10 represents the worst possible pain. During the postoperative period, if NRS ≥ 4 occurs, 100 mg of tramadol will be administered intravenously. This situation will be defined as the need for rescue analgesia.

    Measured: 36 hours

  4. Duration of rebound pain

    Pain will be evaluated using the 0-10 Numerical Rating Scale (NRS), where 0 represents no pain and 10 represents the worst possible pain. Rebound pain will be defined as a short-term but severe pain occurring before and after the resolution of the interscalene block (NRS ≥ 7). The duration of rebound pain experienced by patients will be recorded in minutes based on the time the pain started and ended, as assessed in a questionnaire directed at the patients.

    Measured: 36 hours

  5. Onset of sensory block

    Duration (minutes) during which there is touch sensation but no pain in the relevant dermatomal areas in the Pin-Prick test.

    Measured: Preoperative time

  6. Onset of motor block

    Duration (minutes) during which motor strength is reduced, but the arm is still movable.

    Measured: Preoperative time

  7. Duration of block effectiveness

    Time (minutes) until the patient reports a significant increase in pain after the block.

    Measured: 36 hours

  8. PONV

    Significant nausea, vomiting, and/or need for rescue antiemetics.

    Measured: 36 hours

  9. Paresthesia

    Observations during the block procedure of 'needle prick, tingling, or electric shock radiating to the arm

    Measured: During the block procedure time

  10. Horner's syndrome

    Miosis and ptosis of the ipsilateral pupil during the perioperative period.

    Measured: Perioperative/Periprocedural

  11. Dyspnea

    Breathing difficulty as described by the patient during the perioperative period.

    Measured: Perioperative/Periprocedural

  12. Hoarseness

    Voice changes described by the patient during the perioperative period.

    Measured: Perioperative/Periprocedural

  13. Intraoperative use of dexmedetomidine

    Ramsey Sedation Scale is a tool used to assess the sedation levels of patients, and it scores from 1 to 6. A score of 1 indicates that the patient is awake, agitated, and very active; a score of 2 indicates that the patient is awake but slightly agitated. A score of 3 indicates that the patient is awake but calm, while a score of 4 indicates that the patient responds but has decreased alertness. A score of 5 indicates that the patient is not awake but responds to stimulation; a score of 6 indicates that the patient is not awake and does not respond to stimuli. In the study, the necessary amount of dexmedetomidine (μg) will be recorded for patients to fall within the 3-4 range on the Ramsey Sedation Scale.

    Measured: Intraoperative time

  14. Pain scores

    Evaluated using a 0-10 Numerical Rating Scale (NRS), where zero represents no pain and ten represents the worst pain imaginable.

    Measured: 36 hours

  15. Duration of stay in the recovery room

    Time from arrival in the recovery room to the point when discharge criteria are met

    Measured: up to 2 hours post surgery

  16. Quality of recovery

    The Quality of Recovery-15 (QoR-15) questionnaire consists of 15 questions rated on a scale of 0-10, with a total score evaluated out of 150. Results are classified as 'excellent' for scores above 135, 'good' for scores between 122-135, 'moderate' for scores between 90-121, and 'poor' for scores below 90.

    Measured: Preoperative day 1, postoperative days 1 and 7.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Mar 2025
  2. Study start20 Mar 2025
  3. Primary completion10 Sep 2025
  4. Study completion20 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
85 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06883279
Sponsor's protocol ID
Rebound pain
Status last verified
Nov 2025
First submitted
9 Mar 2025
Last updated
17 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Intraplexus and Extraplexus in people with Anesthesia and Pain, Shoulder, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rebound pain (time frame: 36 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in